Hospira Inc.'s (HSP) plans to launch a generic version of the Sanofi-Aventis SA (SNY) colon-cancer drug Eloxatin in the U.S. have been put on hold due to a legal challenge from Sanofi.
Hospira disclosed the delay in a regulatory filing with the Securities and Exchange Commission late Friday, only days after it announced Food and Drug Administration approval to launch the injectable drug, known generically as oxaliplatin.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
The company also disclosed a warning letter from the FDA relating to problems with power cords used on drug infusion pumps, which it recalled. But it said neither the drug delay or power cord issue should hurt its ability to reach recently announced 2009 financial goals, which include a raised full-year earnings projection.
Hospira said it was launching generic oxaliplatin domestically, and that it had one of the first generic versions of the drug in solution form. Hospira noted that the drug racked up about $1.4 billion in U.S. sales for Sanofi last year.
Three days later, Hospira said it received notice from the FDA that the company's oxaliplatin application was suspended due to "legal proceedings initiated by the innovator company against the FDA" and a court order issued in that proceeding.
StockEinstein.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
